Document is current
Any future updates will be listed below
-
Authors
Fan, Moli
Zhang, Hao
Shi, Yutong
Huang, Xiaoyu
Cui, Ying
Yu, Zihao
Zhang, Xiao-He
Zhang, Xiao-Jing
Xue, Ying-Ping
Huang, Lei
Shi, Fu-Dong
Qi, Guo-Yan
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China ((No. 82274582)
S&T Program of Hebei central guidance for local scientific and technological development funding projects (No. 246Z7706G)
the Key Laboratory Construction Subsidy Fund Project (No. 236790017H)
- License Information
-
More Information
Article History
Received: 12 July 2025
Accepted: 10 November 2025
First Online: 16 December 2025
Declarations
:
: This study was approved by the Ethics Committee of Tianjin Medical University General Hospital (No. IRB2025-YX-012-01) and formal waiver of informed consent was granted by the institutional review board.
: Not applicable.
: FDS received honoraria (lectures, advisory boards, consultations) from Alexion/AstraZeneca, Novartis, Hansoh Pharmaceutical, Sinomab and Lundbeck. He received research grants from Zai Lab, AstraZeneca, Novartis, Biogen. FDS was a co-founder of New Terrain from August, 2018 to December, 2019; Akriva from November, 2023 to September, 2025. He also serves as the current section chair of national network of Neuroimmunology, under Chinese neurological association from 2020 to present and as a board member of European Charcot Foundation from 2023 to present. All other authors declare no competing interests.
